VIAGRA (Sildenafil Citrate) PROFILE - BUY ONLINE VIAGRA

Sildenafil is used to treat male sexual function problems (impotence or erectile dysfunction) by blocking a certain enzyme (phosphodiesterase-PDE5) in the body. In combination with sexual stimulation, sildenafil works by helping the blood flow into the penis to achieve and maintain an erection.
As well as treating impotence, Sildenafil Citrate can also be effective in treating Pulmonary Arterial Hypertension (PAH).  Similarly to how it acts to relax muscles of the penis, it relaxes arterial walls; therefore, reducing resistance and pressure in the arteries.
Sildenafil Citrate is solely active in relaxing muscles and increasing blood flow to the heart, lungs and penis due to PDE-5, yet vasodilation is not increased in other parts of the body.

VIAGRA (Sildenafil Citrate) DOSAGE, How to use

 Read the Patient Information Leaflet provided by your pharmacist before you start taking sildenafil and each time you get a refill. If you have any questions, consult your doctor or pharmacist. Viagra is to be taken 30 minutes to 1 hour before sexual activity. You may take it up to 4 hours before sexual activity. Viagra is not supposed to be taken more often than once per day. Avoid eating grapefruit or drinking grapefruit juice while you are being treated with this medication unless your doctor instructs you otherwise.The dosage is based on your medical condition, response to therapy, and other medications you may be taking (see also Drug Interactions section). Consult your doctor or pharmacist for more details.

VIAGRA SIDE EFFECTS

From extensive clinical trials, the most commonly reported cardiovascular adverse events in patients treated with sildenafil were headache (16%), flushing (10%), and dizziness (2%). The incidences of hypotension, orthostatic hypotension, and syncope and the rate of discontinuation of treatment due to adverse events were <2% and were the same in patients taking sildenafil and those taking placebo. Retrospective analysis of the concomitant use of antihypertensive medications (beta blockers, alpha blockers, diuretics, angiotensin-converting enzyme inhibitors, and calcium antagonists) in patients taking sildenafil did not indicate an increase in the reports of adverse events or significant episodes of hypotension compared with patients treated with sildenafil alone. In clinical trials, the incidence of serious cardiovascular adverse events, including stroke and myocardial infarction, was the same for patients treated with sildenafil or placebo. Concurrent disease states, such as renal or hepatic impairment, or concomitant use of inhibitors of the cytochrome P450 isozyme CYP3A4 could increase systemic exposure to sildenafil. Since the US market launch in April 1998, monitoring of spontaneous adverse event reports in association with sildenafil has demonstrated a pattern that is generally consistent with the experience observed during clinical development, with the exception of infrequent reports of priapism. In conclusion, extensive clinical testing has shown that overall treatment with sildenafil for up to 1 year is well tolerated and is associated with a low incidence of adverse events that result in discontinuation of treatment in <3% of patients.